clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Hernia, Hiatal D006551 3 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Hemophilia A D006467 10 associated lipids
Hemolysis D006461 131 associated lipids
Heart Failure D006333 36 associated lipids
Hearing Loss, Sensorineural D006319 8 associated lipids
Hearing Disorders D006311 10 associated lipids
Hand Dermatoses D006229 5 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Giardiasis D005873 3 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Gastritis D005756 27 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Fractures, Open D005597 3 associated lipids
Foot Diseases D005534 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Braden B The best and worst treatments for Helicobacter pylori. 2015 BMJ pmid:26290321
Zhang T Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for atorvastatin and its metabolites. 2015 Eur J Pharm Sci pmid:26116278
Fraser LA et al. Calcium channel blocker-clarithromycin drug interaction did not increase the risk of nonvertebral fracture: a population-based study. 2015 Ann Pharmacother pmid:25429094
Lee SJ et al. Clarithromycin Attenuates Radiation-Induced Lung Injury in Mice. 2015 PLoS ONE pmid:26114656
Tojima I et al. Anti-inflammatory effects of a novel non-antibiotic macrolide, EM900, on mucus secretion of airway epithelium. 2015 Auris Nasus Larynx pmid:25769240
Nonaka L et al. Novel macrolide-resistance genes, mef(C) and mph(G), carried by plasmids from Vibrio and Photobacterium isolated from sediment and seawater of a coastal aquaculture site. 2015 Lett. Appl. Microbiol. pmid:25765542
Tsunemine H et al. [Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)]. 2015 Gan To Kagaku Ryoho pmid:25981655
Ribaldone DG et al. Efficacy of amoxycillin and clarithromycin-based triple therapy for Helicobacter pylori eradication: a 10-year trend in Turin, Italy. 2015 Panminerva Med pmid:25971330
Thellin O et al. In vitro approach to study the synergistic effects of tobramycin and clarithromycin against Pseudomonas aeruginosa biofilms using prokaryotic or eukaryotic culture media. 2015 Int. J. Antimicrob. Agents pmid:25963337
Hwang JJ et al. Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease. 2015 World J. Gastroenterol. pmid:25945019
Molina-Infante J et al. Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. 2015 Aliment. Pharmacol. Ther. pmid:25776067
Takahashi C et al. Observation of antibacterial effect of biodegradable polymeric nanoparticles on Staphylococcus epidermidis biofilm using FE-SEM with an ionic liquid. 2015 Microscopy (Oxf) pmid:25757698
Zhou Z et al. Macrolide-resistant Mycoplasma pneumoniae in adults in Zhejiang, China. 2015 Antimicrob. Agents Chemother. pmid:25451048
Hur J et al. Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. 2015 Chem. Res. Toxicol. pmid:25811541
Trespalacios AA et al. Improved allele-specific PCR assays for detection of clarithromycin and fluoroquinolone resistant of Helicobacter pylori in gastric biopsies: identification of N87I mutation in GyrA. 2015 Diagn. Microbiol. Infect. Dis. pmid:25600075
Yoshida S et al. Investigation of the population structure of Mycobacterium abscessus complex strains using 17-locus variable number tandem repeat typing and the further distinction of Mycobacterium massiliense hsp65 genotypes. 2015 J. Med. Microbiol. pmid:25596119
Ontsira Ngoyi EN et al. Molecular Detection of Helicobacter pylori and its Antimicrobial Resistance in Brazzaville, Congo. 2015 Helicobacter pmid:25585658
Spaniol V et al. Moraxella catarrhalis AcrAB-OprM efflux pump contributes to antimicrobial resistance and is enhanced during cold shock response. 2015 Antimicrob. Agents Chemother. pmid:25583725
Chu HS et al. Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense. 2015 PLoS ONE pmid:25581038
Lee H et al. Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. 2015 Dig Liver Dis pmid:25467826
Kobayashi M et al. A sudden cardiac death induced by sildenafil and sexual activity in an HIV patient with drug interaction, cardiac early repolarization, and arrhythmogenic right ventricular cardiomyopathy. 2015 Int. J. Cardiol. pmid:25464498
Mailleux M et al. Unusual pulmonary toxicity of ipilimumab treated by macrolides. 2015 Acta Clin Belg pmid:26790556
Gisbert JP et al. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy. 2015 Dig. Dis. Sci. pmid:25236423
Ersal T et al. Fatal disseminated infection with Fusarium petroliphilum. 2015 Mycopathologia pmid:25234793
Baumann M et al. Aquatic toxicity of the macrolide antibiotic clarithromycin and its metabolites. 2015 Chemosphere pmid:25051235
Kakked GA et al. Pneumobilia with gastric outlet obstruction. 2015 BMJ Case Rep pmid:26552878
Rubio M et al. Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Complex. 2015 PLoS ONE pmid:26448181
Blair PW et al. DRESS syndrome presenting after initiation of mycobacterium avium complex osteomyelitis treatment. 2015 BMJ Case Rep pmid:26438676
Zhi D et al. The enhancement of cardiac toxicity by concomitant administration of Berberine and macrolides. 2015 Eur J Pharm Sci pmid:25976224
Dingemanse C et al. Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice. 2015 Carcinogenesis pmid:26320104
Obregón-Henao A et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. 2015 Antimicrob. Agents Chemother. pmid:26303795
Pea F et al. Everolimus overexposure in a heart transplant patient receiving clarithromycin for the treatment of pneumonia. 2015 Transpl Infect Dis pmid:26296391
Picoli SU et al. Resistance to amoxicillin, clarithromycin and ciprofloxacin of Helicobacter pylori isolated from Southern Brazil patients. 2014 May-Jun Rev. Inst. Med. Trop. Sao Paulo pmid:24878996
UÄŸurlu T et al. Optimization and evaluation of clarithromycin floating tablets using experimental mixture design. 2014 Mar-Apr Acta Pol Pharm pmid:25272652
Skvarc M et al. Multi locus sequence typing (MLST) used as a tool to confirm the ability of susceptible Helicobacter pylori strains to gain resistance to clarithromycin during eradication therapy. 2014 Jan-Feb Hepatogastroenterology pmid:24895826
Kakuda TN et al. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies. 2014 J. Antimicrob. Chemother. pmid:24155058
Kathariya R et al. Evaluation of subgingivally delivered 0.5% clarithromycin as an adjunct to nonsurgical mechanotherapy in the management of chronic periodontitis: a short-term double blinded randomized control trial. 2014 J Investig Clin Dent pmid:23097216
Maev IV et al. [Eradication therapy for Helicobacter pylori infection: review of world trends]. 2014 Ter. Arkh. pmid:24779078
Katagiri S et al. [Case report; Disseminated Mycobacterium abscessus infection with hemophagocytic syndrome during treatment of chronic lymphocytic leukemia]. 2014 Nippon Naika Gakkai Zasshi pmid:24796145
Altman E et al. Lipopolysaccharide glycotyping of clarithromycin-resistant and clarithromycin-susceptible Canadian isolates of Helicobacter pylori. 2014 Can. J. Microbiol. pmid:24392924
Veraldi S et al. Treatment of sporotrichoid fish tank granuloma with pulsed clarithromycin. 2014 Dermatology (Basel) pmid:25228273
Phillips RO et al. Reply to "compliance with antimicrobial therapy for buruli ulcer". 2014 Antimicrob. Agents Chemother. pmid:25225343
Elkhatib W and Noreddin A Efficacy of ciprofloxacin-clarithromycin combination against drug-resistant Pseudomonas aeruginosa mature biofilm using in vitro experimental model. 2014 Microb. Drug Resist. pmid:25050970
Ohe M and Bohgaki T Successful treatment with clarithromycin for patients with polymyalgia rheumatica. 2014 Korean J. Intern. Med. pmid:25045305
Dalbøge CS et al. Pharmacokinetic variability of clarithromycin and differences in CYP3A4 activity in patients with cystic fibrosis. 2014 J. Cyst. Fibros. pmid:24035278
DiCicco M et al. In vitro synergism of fosfomycin and clarithromycin antimicrobials against methicillin-resistant Staphylococcus pseudintermedius. 2014 BMC Microbiol. pmid:24886369
Noonan KA et al. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. 2014 Cancer Immunol Res pmid:24878583
Gong EJ et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change? 2014 J. Korean Med. Sci. pmid:24851029
Tursi A et al. Decreasing efficacy of the standard seven-day triple therapy containing amoxycillin and clarithromycin in curing Helicobacter pylori infection in clinical setting in Italy: a 10-year follow-up study. 2014 Panminerva Med pmid:24637473
Wei Z et al. Rome III criteria cannot distinguish patients with chronic gastritis from those functional dyspepsia patients. 2014 Helicobacter pmid:24617669